Czech AATD Registry

Recruiting now

Conditions studied: Alpha-1-antitrypsin Deficiency

In brief

Alpha-1-antitrypsin deficiency is the most common congenital disease of the respiratory system, leading to early pulmonary emphysema or bronchiectasis. Pulmonary involvement significantly accelerates active cigarette smoking. Patients with alpha-1-antitrypsin deficiency may also have liver cirrhosis, vasculitis, skin or intestinal disorders. The AATD Registry is a non-interventional multicenter retrospective prospective longitudinal follow-up of patients with alpha-1-antitrypsin deficiency. The aim of the AATD National Registry is to collect and analyze clinical data in patients with alpha-1 antitrypsin deficiency.

Key facts

Study ID

NCT05178277

Run by

Thomayer University Hospital

People needed

300

Starts

2018-01-01

Expected to finish

2035-12-31

Last updated by the study team

2022-01-05

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with alpha-1-antitrypsin deficiency

You may not qualify if…

• Patient disagreement with inclusion in the study

Where it is running

• Thomayer university hospital — Prague, Czech Republic, Czechia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.